Affimed: Surges on positive initial data from cancer drug study

Lifeist Wellness

09/04/2021 12:03

** U.S.-listed shares of Affimed N.V  AFMD.O  rise ~27% to
$10.02 premarket
    ** Co reports positive initial data from early-stage trial
of lead cancer therapy, AFM13, in combination with natural
killer (NK) cells in patients with a form of cancer that affects
white blood cells (https://refini.tv/3t5LSHZ)
    ** NK cells are a type of white blood cells that help in
controlling several types of tumors and microbial infections
    ** Data presented at American Association for Cancer
Research (AACR) annual meeting
    ** All four patients experienced significant disease
reduction, with two complete responses and two partial responses
- AFMD
    ** There were no observed events of cytokine release
syndrome, neurotoxicity syndrome or graft-versus-host disease
    ** Study is continuing enrollment of second dose cohort
    ** AFM13 was granted "orphan drug" status by U.S. FDA in
April, 2020

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))